Abstract
BackgroundNucleobindin 2 (NUCB2) abnormal expression has been reported in gastric cancer and breast cancer. However, the role of NUCB2 in prostate cancer (PCa) remains unclear. The aim of the present study was to investigate the NUCB2 expression in PCa tissues and adjacent non-cancerous tissues and its potential relevance to clinicopathological variables and prognosis.MethodsNUCB2 mRNA expression was determined by real-time quantitative real time reverse transcriptase polymerase chain reaction in 180 pairs of fresh frozen PCa tissues and corresponding non-cancerous tissues. Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between NUCB2 expression and prognosis of PCa patients.ResultsOur results showed that the expression level of NUCB2 mRNA in PCa tissues was significantly higher than those in non-cancerous tissues. Our results indicated that the high expression of NUCB2 in PCa was associated with lymph node metastasis, preoperative PSA, Gleason score, and angiolymphatic invasion. Kaplan–Meier survival analysis showed that patients with high NUCB2 expression have shorter biochemical recurrence (BCR)-free survival time compared to patients with low NUCB2 expression. Multivariate analysis revealed that NUCB2 expression was an independent predictor of BCR-free survival.ConclusionsNUCB2 might play a positive role in PCa development and could serve as an independent predictor of BCR-free survival.
Highlights
Nucleobindin 2 (NUCB2) abnormal expression has been reported in gastric cancer and breast cancer
We investigated the relationship between NUCB2 mRNA expression status and commonly used clinicopathological parameters in prostate cancer (PCa)
The upregulation of NUCB2 mRNA in PCa tissues was correlated with the higher Gleason score (P < 0.001), the higher level of preoperative prostate-specific antigen (PSA) (P = 0.004), the positive lymph node metastasis (P = 0.022), and the positive angiolymphatic invasion (P = 0.004)
Summary
Nucleobindin 2 (NUCB2) abnormal expression has been reported in gastric cancer and breast cancer. Carcinogenesis and mechanisms influencing progression and prognosis of PCa are a multi-step process, involving both genetic insults to epithelial cells and changes in epithelial-stromal interactions [2]. Conventional prognostic factors such as Gleason score, preoperative PSA levels or ratio of involved biopsies only insufficiently predict patient outcome for currently available therapies. They are even more limited in identifying insignificant PCa. there is an urgent need for better understanding of PCa pathogenesis which may lead to more effective treatment strategies [3,4,5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
